Attaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cells, according to a new study published in Nanoscale. The study, conducted in partnership by researchers at Nemours Children’s Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.
“High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor. This research demonstrates a novel method of treating this tumor without the toxicity of aggressive therapy that can also have late effects on the patient’s health,” said Tamarah J. Westmoreland, MD, PhD, a pediatric surgeon at Nemours Children’s Health System and senior author of the study. “Unique approaches to target tumor cells with nanoparticle delivery systems hold promise for treatment of resistant tumors, such as the high risk neuroblastoma. We are hopeful that in the future, nanoparticles can be utilized to personalize care to patients and reduce the late effects of therapy.”
Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys. About 700 new cases of neuroblastoma are diagnosed each year in the United States and most cases appear in children younger than 5 years old. High-risk neuroblastoma is hard to cure and is more likely to become resistant to standard therapies or recur. These cancers are also associated with late effects after treatments have ended, including developmental delays, hearing loss, or other disabilities.
Curcumin has been shown to have substantial anti-cancer ability, but its low solubility and poor stability have made its use in medicinal applications challenging. Researchers from Nemours and UCF found that nanoparticles can be used to deliver curcumin to tumor sites.
“This shows that nanoparticles can be an effective delivery vehicle for cancer drugs,” said Professor Sudipta Seal, who directs of UCF’s NanoScience Technology Center and Advanced Materials Processing Analysis Center, and is a collaborator on the study. “More research is needed, but we are hopeful it could lead to more effective treatment of this devastating disease in the future.”
In the study, researchers loaded Cerium oxide nanoparticles with curcumin and coated them with dextran to test in cell lines of a high-risk form of neuroblastoma, known as MYCN-amplified, as well as non-amplified neuroblastoma. This formulation induced substantial cell death in neuroblastoma cells while producing no or only minor toxicity in healthy cells. Overall, the nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.
Nanoscience research, which explores the unusual properties of materials at the nanoscale, has led to advancements in medicine, energy, information storage, computing and other fields. At no more than 100 nanometers, nanoparticles are exceedingly small. By comparison, a sheet of paper is about 75,000 nanometers thick.
This study was conducted in a laboratory setting in Orlando, at Nemours Children’s Hospital and the University of Central Florida in cells from children with neuroblastoma, but researchers hope to begin to use these curcumin nanoparticles with micro RNA in animal models to direct the molecule to a tumor site.
The Latest on: Neuroblastoma
- UW researchers participate in clinical trial for new treatment to combat neuroblastomaon November 19, 2020 at 9:45 am
The new trial, which is being conducted by University of Wisconsin School of Medicine and Public Health researchers, is investigating a combination of radiation therapy and immunotherapy to treat the ...
- Growth in the Neuroblastoma Drugs Market to be Driven with the Rising Prevalence of Childhood Cancers by 2020-2028on November 18, 2020 at 6:29 pm
Nov 18, 2020 (AB Digital via COMTEX) -- Research Nester published a report titled “Neuroblastoma drugs market- Global Demand Analysis and Opportunity Outlook 2020-2028” which delivers detailed ...
- Family of girl, four, suffering with stage four neuroblastoma say she may not get treatment she needs because Covid lockdown hit efforts to raise £230,000 for potentially life ...on November 17, 2020 at 2:44 am
Nellie-Rose Culleton is undergoing gruelling treatment for neuroblastoma, a rare cancer affecting around 100 UK children each year. But her family have struggled to raise the funds needed to ...
- Family of girl with neuroblastoma say she may not get treatment as Covid hit fundraising effortson November 17, 2020 at 2:44 am
Rose Culleton was diagnosed with the rare cancer neuroblastoma two days before the UK went into lockdown in March. Her family from Maidstone, Kent, are fundraising for treatment in New York.
- Pediatric Cancer Researchers Receive $1.3 Million to Study Precise Treatment for Neuroblastomaon November 16, 2020 at 7:11 am
PRNewswire/ -- Today Children’s Hospital of Philadelphia (CHOP) and Gustave Roussy, a cancer-research institute based in France, were awarded a grant from a group of neuroblastoma clinical research ...
- Pediatric Cancer Researchers Receive $1.3 Million to Study Precise Treatment for Neuroblastomaon November 16, 2020 at 7:02 am
This is the first-ever collaboration between the North American and European pediatric cancer consortia focused on neuroblastoma. The grant, distributed over a four-year period, will be split ...
- Neuroblastoma Drugs Market: Market Competition, Competitive Scenario, Emerging Trends And Future Opportunities Till 2028on November 10, 2020 at 11:25 pm
Comserve Inc. / -- The market for neuroblastoma drugs is anticipated to record a notable CAGR of around 4% over the ...
- BeiGene application for neuroblastoma drug accepted in Chinaon November 9, 2020 at 8:19 am
marketing application seeking approval of dinutuximab beta for the treatment of high-risk neuroblastoma patients at least 12 years old. The targeted immunotherapy, branded as Qarziba in Europe by ...
via Google News and Bing News